---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030831"
form_type: "8-K"
ticker: "SCNX"
cik: "0001382574"
company_name: "Scienture Holdings, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:06:55.063289+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TRxADE Q3 2022: revenue $2.4M (-6% YoY), gross margin 58%, net loss ($0.06)/share, adj EBITDA ($0.4M)

## Summary
- Revenue decreased 6% to $2.4M from $2.6M; gross margin improved to 58% from 50%.
- Net loss narrowed to ($0.5M) or ($0.06) per share vs ($1.3M) or ($0.16) per share YoY.
- Adjusted EBITDA turned negative at ($0.4M) compared to positive $0.7M in Q3 2021.
- Added 291 new registered members in Q3; total ~14,100+; Bonum Health signed telemedicine deal with ShopRite.
- Bonum Health entered distribution agreements with multiple insurance brokerage firms for employer groups in Oct 2022.

## SEC filing metadata
- accession: 0001493152-22-030831
- form_type: 8-K
- ticker: SCNX
- cik: 0001382574
- company_name: Scienture Holdings, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382574/000149315222030831/0001493152-22-030831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382574/000149315222030831/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030831
- JSON: https://secwatch.observer/filing/0001493152-22-030831.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030831.txt

## Key facts
- Earnings Releases
  Scienture Holdings, Inc. reported for the three and nine months ended September 30, 2022 results: revenue $2.4 million, net income ($0.5) million, EPS ($0.06) per basic and diluted share.
  - Period: for the three and nine months ended September 30, 2022
  - Revenue: $2.4 million
  - Net income: ($0.5) million
  - EPS: ($0.06) per basic and diluted share
  - Result: reported results
  source text: growth opportunities.” Third Quarter 2022 Financial Summary Consolidated revenues for the third quarter of 2022 compared to the third quarter of 2021, decreased 6% to $2.4 million, compared to $2.6 million, respectively. The consolidated decrease in revenue, is driven by decreases in revenue attributed to our TRxADE Prime and Community Specialty Pharmacy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382574/000149315222030831/0001493152-22-030831-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.